Cargando…

P1345: EFFECT OF DECITABINE ON MACROPHAGE PHENOTYPE AND FUNCTION IN VITRO IN THE CONTEXT OF AML

Detalles Bibliográficos
Autores principales:	Hilberink, Jacobien, Weinhäuser, Isabel, Pereira-Martins, Diego, Jacob Schuringa, Jan, Huls, Gerwin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430543/ http://dx.doi.org/10.1097/01.HS9.0000972268.56144.71

Ejemplares similares

P466: THE INTRINSICALLY DISORDERED TRANSCRIPTIONAL REGULATOR MN1 DEPENDS ON THE CHAPERONE DNAJB6B FOR ITS FULL TRANSFORMING POTENTIAL
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

High ME1 Expression Is a Molecular Predictor of Post-Transplant Survival of Patients with Acute Myeloid Leukemia
por: Ortiz Rojas, César Alexander, et al.
Publicado: (2022)

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
por: Hilberink, Jacobien R., et al.
Publicado: (2023)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy
por: Lima, Keli, et al.
Publicado: (2022)

Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability
por: Erdem, Ayşegül, et al.
Publicado: (2022)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

1345. Patient Perspectives and Journey with Influenza and Seeking Care from US National Survey
por: Way, Nate, et al.
Publicado: (2021)

1345. Impact of the COVID-19 Pandemic on Pediatric Ambulatory Antibiotic Use in an Academic Health System
por: Katz, Sophie E, et al.
Publicado: (2020)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones
por: Houtsma, Roos, et al.
Publicado: (2022)

ELMO1 Is Upregulated in AML CD34+ Stem/Progenitor Cells, Mediates Chemotaxis and Predicts Poor Prognosis in Normal Karyotype AML
por: Capala, Marta E., et al.
Publicado: (2014)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
por: Li, Hongjiao, et al.
Publicado: (2023)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

P1350: M2-LIKE MONOCYTE-DERIVED MACROPHAGES PROTECT AML CELL LINES AND PRIMARY AML CELLS AGAINST THERAPY-INDUCED APOPTOSIS
por: Miari, Katerina, et al.
Publicado: (2023)

Decitabine Promotes Modulation in Phenotype and Function of Monocytes and Macrophages That Drive Immune Response Regulation
por: Zambuzi, Fabiana Albani, et al.
Publicado: (2021)

PB1772: HIGH SLIT2 LEVELS ARE ASSOCIATED WITH GMP LIKE AML AND TREATMENT WITH RECOMBINANT SLIT2 INHIBITS LEUKEMOGENESIS
por: Simoes, Luise Araujo de Albuquerque, et al.
Publicado: (2023)

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
por: Kang, Synat, et al.
Publicado: (2022)

Medicine before the plague: practitioners and their patients in the crown of Aragon 1285–1345
por: O'Boyle, Cornelius
Publicado: (1995)

The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis
por: de Boer, Bauke, et al.
Publicado: (2020)

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS
por: Mims, Alice, et al.
Publicado: (2023)

P502: PHASE II STUDY ON VENETOCLAX PLUS DECITABINE FOR ELDERLY (≥60 <75YEARS) PATIENTS WITH NEWLY DIAGNOSED HIGH-INTERMEDIATE RISK AML ELEGIBLE FOR ALLO-SCT: MIDTERM UPDATE OF VEN-DEC GITMO STUDY
por: Russo, Domenico, et al.
Publicado: (2023)

CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones
por: Houtsma, Roos, et al.
Publicado: (2021)

P1345: IMMUNE RECONSTITUTION AFTER BMT FOR NON-MALIGNANT HEMATOLOGICAL CONDITIONS FOR RELATED, UNRELATED AND HAPLOIDENTICAL DONORS. A STUDY IN THE PEDIATRIC DEPARTMENT AT ST MARY’S HOSPITAL BETWEEN 2019&2020
por: Khoder, A., et al.
Publicado: (2022)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

P407: MITOTIC FIDELITY IS A RESISTANCE MECHANISM TO DECITABINE IN MYELOID TUMORS.
por: Yabushita, Tomohiro, et al.
Publicado: (2023)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea‐induced t‐MDS/AML
por: Horton, Joshua D., et al.
Publicado: (2015)

Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
por: Zhao, Chenchen, et al.
Publicado: (2019)

Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1
por: Mpakou, Vassiliki, et al.
Publicado: (2021)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
por: Jonas, Brian A., et al.
Publicado: (2023)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

P1161: THERAPY AND OUTCOME IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A CONTEMPORARY AND NATIONWIDE POPULATION-BASED STUDY IN THE NETHERLANDS.
por: Brink, Mirian, et al.
Publicado: (2023)

P1415: HIGH AND LOW MYELOID SKEWING IN THE GENERAL POPULATION AND THE ASSOCIATION WITH CLONAL HEMATOPOIESIS
por: van Bergen, M., et al.
Publicado: (2022)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2023)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kempt7cjo7mf9k3hhcmo19oaq0